PI5P4K inhibitors: promising opportunities and challenges

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Phosphatidylinositol 5-phosphate 4-kinases (PI5P4K) are enzymes that convert PI5P to PI(4,5)P2.
• The PI5P4K family has three mammalian isozymes (α, β, γ) that use GTP and ATP as phosphodonors.
• PI5P4Kβ uniquely senses GTP levels, impacting its kinase activity.

Purpose of the Study:

• To provide an analytical overview of PI5P4K isozymes' distinct roles.
• To review recent developments in PI5P4K inhibitors.
• To address challenges in PI5P4K inhibitor development and promote targeted therapeutic strategies.

Main Methods:

• Review of existing literature on PI5P4K isozymes and inhibitors.
• Analysis of structural insights into PI5P4K inhibitors.
• Discussion of pharmacodynamic marker identification for in vivo assessment.

Main Results:

• PI5P4Kα and β are critical in tumorigenesis; PI5P4Kγ regulates immune and neural systems.
• Pharmacological targeting of PI5P4K offers therapeutic potential for cancer, immune dysfunction, and neurodegenerative diseases.
• Challenges in PI5P4K inhibitor development include discrepancies in efficacy due to inhibitor design and assessment methods.

Conclusions:

• Understanding individual isozyme roles is key for targeted PI5P4K therapies.
• Overcoming challenges in inhibitor development requires addressing ATP levels, non-catalytic functions, and pharmacodynamic markers.
• Further research into structural insights and pharmacodynamic markers is essential for effective PI5P4K-targeted therapeutics.